Rebecca Cohen
Investor Relations Contact at IKENA ONCOLOGY, INC.
Profile
Rebecca Cohen is currently working as an Investor Relations Contact at Ikena Oncology, Inc. She previously worked as a Director at Jewish Big Brothers Big Sisters of Greater Boston and Solomon Schechter Day School of Greater Boston.
In 2017, she was the Head-Corporate & Investor Relations at SQZ Biotechnologies Co. She also served as the IR & Corporate Communications Contact at Epizyme, Inc. and Head-Clinical & Medical Affairs at Mesoblast Ltd.
Ms. Cohen completed her undergraduate degree at Rutgers State University of New Jersey.
Rebecca Cohen active positions
| Companies | Position | Start |
|---|---|---|
| IKENA ONCOLOGY, INC. | Investor Relations Contact | - |
Former positions of Rebecca Cohen
| Companies | Position | End |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Investor Relations Contact | 2018-06-30 |
| EPIZYME, INC. | Public Communications Contact | 2016-04-30 |
| Jewish Big Brothers Big Sisters of Greater Boston | Director/Board Member | - |
| Solomon Schechter Day School of Greater Boston | Director/Board Member | - |
| MESOBLAST LIMITED | Chief Tech/Sci/R&D Officer | - |
Training of Rebecca Cohen
| Rutgers State University of New Jersey | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| IKENA ONCOLOGY, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
| Jewish Big Brothers Big Sisters of Greater Boston | |
| Solomon Schechter Day School of Greater Boston |
- Stock Market
- Insiders
- Rebecca Cohen
